Alacrita

Prior to forming Alacrita, Rob was Head of Business Development at Onyvax Ltd, a biotechnology company specialising in the development of complex biopharmaceuticals to treat cancer. At Onyvax he supported scientific teams with the identification, negotiation and management of R&D collaborations and out-sourcing contracts. He also had primary responsibility for in-licensing, out-licensing and M&A.

At Alacrita, Rob has led and managed a number of consulting projects across broad functional disciplines, including regulatory affairs, clinical development and business development. Projects in which Rob has played a leading role include:

• In-licensing support and due diligence for a North American company searching for early stage oncology assets
• Business development and marketing roadmap for a vaccine services provider
• Licensing of a technology platform from a university into a new start-up
• Due diligence on a cell therapy reagents company
• Commercial due diligence on a novel diabetes product
• Literature review and KOL interviews to develop clinical strategy for a novel oncology drug
• Business plan and investor presentation to support a Series B financing for a European oncology company
• Biotechnology strategy and biosafety regulatory framework for an emerging economy
• Set out a commercialisation roadmap for a novel, recombinant biomaterial

Rob Johnson has a BSc in biochemistry from the University of Nottingham.